Business
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first
About this update from Ani Pharmaceuticals, Inc.
[{"type":"text","content":" BAUDETTE, Minn.--(BUSINESS WIRE)--\nANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2022 financial results on Tuesday, May 10, 2022.\n\nNikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:\n\nDate: Tuesday, May 10, 2022\nTime: 8:30 a.m. ET\nToll free (U.S.): 866-342-8591\nWebcast (live and replay): www.anipharmaceuticals.com, under the “Investors” section\n\nA replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-753-4606 and entering access code 5146584.\n\nAbout ANI\nANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin™ Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220419005351/en/\n\nInvestor Relations Contact:\nLisa M. Wilson, In-Site Communications, Inc.\n212-452-2793\[email protected]\n\nMedia Contact:\nAngela Salerno-Robin\ndna Communications\n212-445-8219\[email protected]\n\nSource: ANI Pharmaceuticals, Inc.","length":3434,"tagName":"div"}]